Name: Name:Nvp-BGJ398
Brand: AABLOCKS
SKU: AA00GU27
Rating: 90 (10 reviews)

Catalog No.: AA00GU27

872511-34-7 | Nvp-BGJ398

Pack Size： 1mg

Purity： 99+%

in stock

$14.00 $10.00

Pack Size： 5mg

Purity： 99+%

in stock

$35.00 $25.00

Pack Size： 10mg

Purity： 99+%

in stock

$51.00 $36.00

Pack Size： 100mg

Purity： 98%

in stock

$329.00 $230.00

Pack Size： 250mg

Purity： 98%

in stock

$567.00 $397.00

Quantity

- +

Add to Card

Order Now

bulk Quotation Request

Technical Information

Catalog Number: AA00GU27

Chemical Name: Nvp-BGJ398

CAS Number: 872511-34-7

Molecular Formula: C26H31Cl2N7O3

Molecular Weight: 560.4754

MDL Number: MFCD22123241

SMILES: CCN1CCN(CC1)c1ccc(cc1)Nc1ncnc(c1)N(C(=O)Nc1c(Cl)c(OC)cc(c1Cl)OC)C

Properties

Complexity: 724

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 0

Defined Bond Stereocenter Count: 0

Formal Charge: 0

Heavy Atom Count: 38

Hydrogen Bond Acceptor Count: 8

Hydrogen Bond Donor Count: 2

Isotope Atom Count: 0

Rotatable Bond Count: 8

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 4.7

Literature fold

Title: Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.

Journal: Journal of medicinal chemistry20111027

Title: Guagnano V, et al. Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6--(4-ethyl-piperazin-1-yl)-phenylamino-pyrimidin-4-yl}-1-me thyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor T

Title: Konecny GE, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12(5):632-42.

Title: Liu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369.